Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762043 · ClinicalTrials.gov registry record · NA
MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments
A NA study, sponsored by Altec.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT04762043: Completed NA study, sponsored by Altec.
NCT04762043 is a NA study that has completed, run by Altec. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04762043, a NA study, has completed, sponsored by Altec.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will evaluate the ability of MyoVoice to replace natural speech. Referred to generally as an Augmentative and Alternative Communication (AAC) device, MyoVoice uses electrical signals recorded non-invasively from speech muscles (electromyographic, or EMG, signals) to restore communication for those with vocal impairments that resulted from surgical treatment of laryngeal and oropharyngeal cancers.
Primary Outcome
Percent accuracy between recognized (sEMG) and ground-truth (acoustic) estimates of fundamental frequency (perceptually known as vocal pitch). Accuracy is estimated on a continuous scale from 0 to 100%.
Interventions
- DEVICE Experimental System: MyoVoice
- DEVICE Reference System: Electrolarynx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-02-12 |
| Est. Completion | 2023-11-08 |
| Phase | NA |
What the finished NCT04762043 record still lists
NCT04762043 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Experimental System: MyoVoice is the first listed.
NCT04762043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04762043 about?
NCT04762043 is a clinical study titled "MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments". This study will evaluate the ability of MyoVoice to replace natural speech. Referred to generally as an Augmentative and Alternative Communication (AAC) device, MyoVoice uses electrical signals recorded non-invasively from speech muscles (electromyographic, or EMG, signals) to restore communication ...
What is the current status of trial NCT04762043?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2021-02-12. Estimated completion is 2023-11-08.
What interventions are being tested in trial NCT04762043?
The interventions under investigation include: Experimental System: MyoVoice (DEVICE), Reference System: Electrolarynx (DEVICE).
Who is sponsoring clinical trial NCT04762043?
This trial is sponsored by Altec, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04762043's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI